Xillix president claims alleged theft of trade secrets by Olympus may affect its survival
This article was originally published in Clinica
Executive Summary
A Canadian cancer detection device manufacturer could be facing a threat to its survival, as it takes legal action against Olympus Optical, its only distributor. Xillix Technologies claims that it was "stunned" by the alleged discovery that the Japanese company had misappropriated trade secrets and filed patents which were potentially competitive.